Bedside-to-bench-to-bedside (reverse translational) immunology-oncology

As a graduate research assistant, I studied systems immuno-oncology in the Liang Lab at MD Anderson Cancer Center, where I follow a “bedside-to-bench-to-bedside” paradigm that
1) applies single-cell/spatial multi-omics and state-of-the-art analytics to dissect systemic immune responses within real-world cancer patients, especially those enrolled in clinical trials;
2) validates and expands cellular and molecular underpinnings of response and resistance to cancer therapeutics with immunogenomic assays and in immunocompetent mouse models;
3) nominates novel therapeutic opportunities for further clinical investigations to create a virtuous cycle.

This approach was established through collaborations with amazing clinical scientists and experimental biologists and was inspired by paradigm-shifting innovations in cancer research during the last decade(s), as summarized below.